Literature DB >> 29506302

[Patent foramen ovele, good reasons to close it].

Bernhard Meier.   

Abstract

A patent foramen ovale (PFO) is not to be considered a disease as it is present in about 25 % of people. Yet, it is the prime reason for paradoxical embolism that can cause serious problems, such as death, stroke, myocardial infarction, and peripheral ischemia. The frequency of such events is probably underestimated as other causes tend to be blamed for them. Device PFO closure can be easily accomplished as outpatient procedure with minimal discomfort and risk and it has been referred to as mechanical vaccination. Randomized trials have proved its value for reduction of recurrent stroke. There is also good evidence that PFO closure solves problems like platypnoea orthodeoxia and exercise desaturation, improves migraine, and is helpful in sleep apnoea. In addition, it renders diving and high altitude climbing safer. The absolute risk of a PFO is dependent on its size and its association with an atrial septal aneurysm, a Eustachian valve, or a Chiari network. The number needed to treat to prevent one stroke by PFO closure may be as low as 2 over lifetime in selected patients. © Georg Thieme Verlag KG Stuttgart · New York.

Entities:  

Mesh:

Year:  2018        PMID: 29506302     DOI: 10.1055/s-0043-121625

Source DB:  PubMed          Journal:  Dtsch Med Wochenschr        ISSN: 0012-0472            Impact factor:   0.628


  3 in total

1.  Impact of percutaneous patent foramen ovale closure on migraine headaches in patients with history of ischemic neurological events.

Authors:  Węglarz Przemysław; Katarzyna Spisak-Borowska; Tomasz Bochenek; Ewa Konarska-Kuszewska; Jerzy Machowski; Maria Trusz-Gluza; Grzegorz Bajor; Katarzyna Mizia-Stec; Joel P Giblett; Patrick A Calvert
Journal:  Postepy Kardiol Interwencyjnej       Date:  2020-10-02       Impact factor: 1.426

2.  The Efficacy of Percutaneous Patent Foramen Ovale Closure on Migraine: a Meta-Analysis of Randomized Controlled Trials and Observational Studies.

Authors:  Quan-Quan Zhang; Jia-Jie Lu; Man-Yun Yan; Xiao-Wei Hu; Yi-Ren Qin; Da-Peng Wang; Jian-Hua Jiang; Qi Fang; Hong-Ru Zhao
Journal:  Biomed Res Int       Date:  2021-03-04       Impact factor: 3.411

3.  Patent Foramen Ovale Closure for Treating Migraine: A Meta-Analysis.

Authors:  Yu Zhang; Haijiao Wang; Ling Liu
Journal:  J Interv Cardiol       Date:  2022-02-02       Impact factor: 2.279

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.